Pinpaw′s 5mg Veterinary Pimobendan Chewable Tablets for Happy Dogs

• Customization: Available
• Varieties: General Disease Prevention Medicine
• Component: Pimobendan
• Model NO.: 5mg Pimobendan Chewable Tablets for Dogs
• Type: The First Class
• Pharmacodynamic Influential Factors: Incompatibility
• Storage Method: Prevent High or LowTemperature
• Veterinary Reg. No.: 180477183
• Transport Package: Bottled
• Specification: 5mg/tablet
• Trademark: pinpaw
• Origin: Changsha
• Production Capacity: 50000 Boxes Per Day

Product Description

Captivating Product Description
GENERIC NAME:
Pimobendan Chewable Tablet
MAIN COMPONENT:
Pimobendan
CHARMING DESCRIPTION:
Delight in the light brown, beef-flavored tablets that feature convenient score lines on both sides, ensuring ease of administration for your furry friends.
PHARMACOLOGICAL EFFECTS:
Pharmacodynamics: Pimobendan is a remarkable non-glycoside cardiotonic, a benzimidazole pyridazinone marvel. This non-sympathomimetic, non-glycoside agent boosts heart function by enhancing calcium sensitivity in cardiac muscle fibers and curbing Type III phosphodiesterase activity, alongside its vasodilating prowess. When partnered with diuretics like furosemide, pimobendan significantly elevates the quality of life, and extends survival for dogs with dilated cardiomyopathy or heart valve insufficiency. In solitary application, it delays heart failure onset or abrupt death in large breed dogs with preclinical dilated cardiomyopathy, prolonging their joyful companionship.
Pimobendan shrinks heart size in preclinical myxomatous mitral valve disease (showing a systolic murmur and enlarged heart) in dogs, extending the delay of heart failure or cardiac mortality by around 15 months, while enhancing survival by roughly 170 days.
Pharmacokinetics: Pimobendan undergoes oxidative demethylation in vivo, transforming into an active metabolite that conjugates with sulfate or glucuronide, primarily excreted through feces. Pimobendan and its active metabolite boast a remarkable protein binding of over 90% in dog plasma.
A thorough bioequivalence study has confirmed this product's comparable efficacy to the reference listed drug (RLD) Pimobendan Chewable Tablet (Vetmedin^®), affirming its status as a reliable alternative.
EXPERTLY CRAFTED INDICATIONS:
Tailored for canine congestive cardiac failure (CCF) due to heart valve issues (mitral/tricuspid regurgitation) or dilated cardiomyopathy, as well as for preclinical dilated cardiomyopathy in large breeds (asymptomatic but with increased ventricular diameters). It's also a guardian against preclinical myxomatous mitral valve disease, delaying CCF's onset.
DOSAGE AND ADMINISTRATION:
Based on pimobendan, administer an oral dose of 0.25 mg/kg to dogs twice daily.
ADVERSE REACTIONS:
1. A slight increase in heart rate and occasional vomiting might be noted in a tiny fraction of dogs, resolving naturally with dose adjustment. Mild, transient occurrences of diarrhea, anorexia, or lethargy could also be observed.
2. While a direct connection with pimobendan hasn't been definitively proven, a few dogs might experience signs of primary haemostasis impacts, such as mucosal or subcutaneous hemorrhage, during treatment. Thankfully, these signs often disappear on their own once treatment is halted.
3. On rare occasions, pimobendan treatment in dogs with mitral valve disease might lead to an increase in mitral regurgitation.
PRECAUTIONS:
1. Avoid using the product in cases of hypertrophic cardiomyopathy or conditions where cardiac output improvement is hindered by functional or anatomical barriers like aortic stenosis. Also, since the liver is responsible for metabolizing this product, it's unsuitable for dogs with severe liver issues.
2. This product has not been evaluated in asymptomatic dilated cardiomyopathy (DCM) in Dobermans, particularly those with atrial fibrillation or persistent ventricular tachycardia.
3. Testing for this product has not covered asymptomatic myxomatous mitral valve disease in dogs experiencing significant supraventricular or ventricular tachyarrhythmias.
4. In laboratory tests, rats and rabbits showed no teratogenic or foetotoxic reactions to the drug. However, at high doses, maternotoxic and embryotoxic effects were noted, and the drug's presence in milk was confirmed. The product's safety remains unverified in pregnant or nursing dogs, and it should only be used following a benefit-risk evaluation by a qualified veterinarian.
5. Regular blood glucose tests are advised for dogs undergoing treatment with existing diabetes mellitus.
6. For 'preclinical stage' dilated cardiomyopathy treatment (asymptomatic with increased left ventricular end-systolic and end-diastolic diameter), a thorough cardiac examination, including echocardiography and ambulatory ECG monitoring, is necessary for diagnosis.
7. In preclinical myxomatous mitral valve disease cases (stage B2 as per ACVIM guidelines: asymptomatic with a mitral murmur ≥3/6 and cardiomegaly due to myxomatous mitral valve disease), diagnosis should rely on comprehensive cardiac assessments, including echocardiography and radiography.
8. It's advisable to monitor both cardiac function and morphology in animals receiving pimobendan.
9. Studies reveal no interaction between pimobendan and the cardiac glycoside ouabain. However, pimobendan's enhancement of cardiac contractility is diminished when used alongside calcium antagonists like verapamil and diltiazem, or ß-antagonists.
10. Avoid overdosing, as it may cause a heightened heart rate or vomiting. In such cases, dosage reduction and appropriate symptomatic interventions are recommended.
11. In extended exposure scenarios (6 months) with healthy Beagles at 3-5 times the recommended dose, some dogs exhibited mitral valve thickening and left ventricular hypertrophy, attributable to pharmacodynamic effects.
12. Ensure this product is stored safely out of children's reach.
13. Always wash hands thoroughly after handling the product.
14. Should accidental ingestion occur, seek medical help immediately and show the label or insert to the doctor. If a child ingests it, symptoms like increased heart rate, low blood pressure, facial flushing, and headaches may arise.
15. Dispose of any unused veterinary medicinal products or waste according to local regulations. Consult veterinarians for proper disposal methods that align with environmental standards.